Companies

New Frontier Data now largest centralised source of cannabis patient data

New Frontier Data has executed an Asset Purchase Agreement to acquire Skylight Health Group’s medical cannabis certification businesses.

New Frontier Data now largest centralised source of cannabis patient data

New Frontier Data is to acquire the medical cannabis business Skylight Health Group Inc. in a move that will make it the largest centralised source of US medical cannabis patient data.

Cannabis industry data, analytics and technology firm, New Frontier Data, has executed an Asset Purchase Agreement to acquire Skylight Health Group’s medical cannabis certification businesses, Canna Care Docs and Relaxed Clarity. 

New Frontier Data plans to apply its comprehensive industry research, technology and consumer engagement capabilities to bring medical cannabis consumption and the growing medical cannabis patient community into focus.

New Frontier Data CEO, Gary Allen, commented: “Access to vital medical cannabis data and the patient insights they represent has been greatly fragmented and difficult for the traditional medical establishment to embrace.

“Continuing our long-standing charge set by our founder Giadha A. DeCarcer to harness a diverse set of critical data sources, this acquisition will allow us to spotlight medical cannabis consumption trends for the constituents we serve today and will tomorrow.”

The company will operate the newly acquired businesses under its new medical data division, CannaMedData, and Cynthia Petrone-Hudock is to leaf the new initiative as Interim CEO of CannaMedData.

Petrone-Hudock said: “While now focused on people, process and technology stabilisation and streamlining, this transition period should be short, allowing us to quickly turn our efforts toward growth and innovation, with the ultimate strategic goal to optimise and maximise capture of cannabis patient data.

“This new and first-of-its-kind aggregate view of medical cannabis consumption enhances our data, research, and analytics, laying the foundation for mainstream medicine to embrace value-based medical cannabis care in the future.”

[activecampaign form=31]

Topicscannabis industrymedical cannabisus

Stephanie Price

Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained".

More from Stephanie

Spotted an error, or have a tip? Contact the newsroom.

Up next · Companies

Brains Bioceutical To List On NASDAQ Via SPAC At US$750m Valuation

Ben Stevens · 6 November 2026

More